Literature DB >> 9124849

Comparative study of pharmacokinetics of two new fluoroquinolones, balofloxacin and grepafloxacin, in elderly subjects.

O Kozawa1, T Uematsu, H Matsuno, M Niwa, S Nagashima, M Kanamaru.   

Abstract

Comparative pharmacokinetics and tolerability were studied in healthy elderly volunteers for two new fluoroquinolones, balofloxacin (Q-35) and grepafloxacin (OPC-17116), the main excretion routes being the renal and hepatic routes, respectively. Both agents were well tolerated in elderly subjects. In comparison with previously reported data from healthy younger adults, the absorption of balofloxacin was slightly delayed and urinary excretion was delayed and diminished. As a significant linear correlation was observed between renal clearance of balofloxacin and creatinine clearance, the delayed and diminished urinary recovery was attributed to the reduced renal function of the elderly subjects enrolled in the study. The absorption of grepafloxacin was also delayed, and the maximum plasma drug concentration and area under the plasma drug concentration-time curve were increased in the elderly by 31 and 48%, respectively, over those in younger adults on the basis of dose normalized to body weight. The plasma terminal elimination half-life and urinary recovery remained unchanged. Decreases in distribution volume and total body clearance in the elderly were considered to be the primary factors contributing to these differences.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9124849      PMCID: PMC163630     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

Review 1.  Pharmacokinetic aspects of newer quinolones.

Authors:  T Uematsu; M Nakashima
Journal:  Prog Drug Res       Date:  1992

Review 2.  Principles of drug therapy in geriatric patients.

Authors:  R W Sloan
Journal:  Am Fam Physician       Date:  1992-06       Impact factor: 3.292

3.  Pharmacokinetics of oral ciprofloxacin, 100 mg single dose, in volunteers and elderly patients.

Authors:  A P Ball; C Fox; M E Ball; I R Brown; J V Willis
Journal:  J Antimicrob Chemother       Date:  1986-05       Impact factor: 5.790

4.  Pharmacokinetics of ciprofloxacin in elderly subjects.

Authors:  M LeBel; G Barbeau; M G Bergeron; D Roy; F Vallée
Journal:  Pharmacotherapy       Date:  1986 Mar-Apr       Impact factor: 4.705

Review 5.  The need for pharmacokinetics protocols in special cases.

Authors:  M B Regazzi; R Rondanelli; M Calvi
Journal:  Pharmacol Res       Date:  1993 Jan-Feb       Impact factor: 7.658

6.  Prescribing for older patients: how to avoid toxic drug reactions.

Authors:  I L Salom; K Davis
Journal:  Geriatrics       Date:  1995-10

7.  Comparative in vitro activities of a new quinolone, OPC-17116, possessing potent activity against gram-positive bacteria.

Authors:  H Wakebe; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

8.  In vitro antibacterial activity of Q-35, a new fluoroquinolone.

Authors:  T Ito; M Otsuki; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

9.  In vitro and in vivo antibacterial activities of a new quinolone, OPC-17116.

Authors:  T Imada; S Miyazaki; M Nishida; K Yamaguchi; S Goto
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

10.  Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: application to pefloxacin in intensive care unit patients.

Authors:  R Bruno; M C Iliadis; B Lacarelle; V Cosson; J W Mandema; Y Le Roux; G Montay; A Durand; M Ballereau; M Alasia
Journal:  J Pharmacokinet Biopharm       Date:  1992-12
View more
  6 in total

1.  The new fluoroquinolones: A critical review.

Authors:  G G Zhanel; A Walkty; L Vercaigne; J A Karlowsky; J Embil; A S Gin; D J Hoban
Journal:  Can J Infect Dis       Date:  1999-05

Review 2.  A critical review of the fluoroquinolones: focus on respiratory infections.

Authors:  George G Zhanel; Kelly Ennis; Lavern Vercaigne; Andrew Walkty; Alfred S Gin; John Embil; Heather Smith; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 3.  Pharmacokinetics and pharmacodynamics of fluoroquinolones.

Authors:  J Turnidge
Journal:  Drugs       Date:  1999       Impact factor: 9.546

Review 4.  Grepafloxacin.

Authors:  A J Wagstaff; J A Balfour
Journal:  Drugs       Date:  1997-05       Impact factor: 9.546

5.  Pharmacokinetics and safety of a new parenteral carbapenem antibiotic, biapenem (L-627), in elderly subjects.

Authors:  O Kozawa; T Uematsu; H Matsuno; M Niwa; Y Takiguchi; S Matsumoto; M Minamoto; Y Niida; M Yokokawa; S Nagashima; M Kanamaru
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

6.  Relationship of quantitative structure and pharmacokinetics in fluoroquinolone antibacterials.

Authors:  Die Cheng; Wei-Ren Xu; Chang-Xiao Liu
Journal:  World J Gastroenterol       Date:  2007-05-07       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.